Reykjavik-based Akthelia Pharmaceuticals and the University of Iceland have been awarded a 6m grant by Horizon Europe to combat antimicrobial resistance (AMR). This occurs when bacteria, viruses, fungi, and parasites evolve and no longer respond to medicines, making infections harder to treat. AMR is listed among the WHOs most pressing health threats of our time, with the potential to give rise to the next global pandemic as pan-drug-resistant strains emerge. Its also estimated that AMR associated infections already contribute to approximately 5 million deaths per year more than AIDS/HIV or malaria. Now, the EU-funded IN-ARMOR project, led by Aktelia…
This story continues at The Next Web
